

DRAFT



Oregon Prescription Drug
Affordability Board






Prescription Drug Affordability Board

2025 Affordability Review Roadmap

April 16, 2025

2025 Affordability Review (AR) Calendar



Review Timeline

April

Set-up for Affordability Reviews

- Board consideration of a second review of the subset list in June to determine if any additional drugs should be removed from AR
 - How to review information to remove additional drugs?
 - Can consider sending out survey to board members on what top 10 drugs they want to review and compile list of most requested Rx's to review
- Board discussion on when public comments should be provided for each drug under review
- Board discussion on timing of vote to identify the nine drugs and at least one insulin product



Review Timeline

April

- Discussion for options to vote to identify 9 drugs and at least one insulin product
- When should the Board vote to identify a drug or insulin product that may cause an affordability challenge?
 - Vote on each drug at the meeting it is presented
 - Vote on each drug at the end of all the reviews
- What should be the order of the drug review? Most costly, most costly by utilization, alphabetic, or other?
- Does that board want to select the Rx independently and then discuss the top-rated ones?



Review Timeline

May

- Board meeting dedicated to consumer and supply chain feedback

June

- Review information about each drug on the AR subset list and determine if any drugs can be removed from the list

If no drugs are removed from the current list, the addition of the selected insulin products may lead to a review of approximately eight drugs each month



Review Timeline

July
to
October

- Review of possibly eight drugs or fewer each month
- Material packets for drugs selected will be discussed
- There will be public comment time for each Rx being reviewed

*(**Board to initially determine if comments will be for each drug or have one public comment time for all drugs and if that time should be at a different time than the public comment time**)*



Review Timeline

November

- Identify nine drugs and a least one insulin product that may create affordability challenges to the Oregon's healthcare system or patient out of pocket costs

December

- Final drug report approved

